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Number of new transgenic mouse strains is
continuously expanding with, as a consequence, a
rapid increase in maintenance cost.
Additionally, as research evolves, some strains are no
more immediately needed.
Mouse embryo cryopreservation represents a way of
response to all these questions:
i/ drastic reduction of maintenance cost,
ii/ protection of cryopreserved lines are from genetic
drift,
iii/ protection again infectious disease.
The GIGA Mouse facility platform has recently
improved its mouse line cryopreservation technique.
The method of embryo cryopreservation by rapid
cooling also called aseptic vitrification has been
selected. Vitrification media, key steps and timing have
been optimized and validated.
After a first partial exposition of the embryos to
cryoprotective solutions, they are immersed in a
vitrifying mixture of penetrating and non-penetrating
cryoprotectants for a short time. The straw containing
the embryos is immediately sealed before to be plunged
in LN2, resulting in a brutal solidification in which
crystallization does not have time to occur.
Various tests are carried out to verify the quality of the cryopreservation procedure. The technique has been validated at GIGA.
Vitrification media are prepared by the platform. Each medium batch is controlled by MEA.
In order to be in compliance with the European Union Tissues and Cells Directives 2006/17/EC and 2006/86/EC, our vitrification
method is now performed aseptically. Aseptic vitrification allows us to avoid any cross-contamination between straws during
the storage and all manipulations. To perform aseptic vitrification, the GIGA Mouse Facility and Transgenics Platform have
recently acquired an UltraSeal 21™ manual sealer for straw to ensure that the health status of cryopreserved embryos is
preserved during the whole cryopreservation procedure: cooling, storage and warming. Regarding strain housed in the
conventional facility, the embryo harvesting can be combined with rederivation.
Straws of each strain are stored in two different LN2 containers. Each straw is clearly identified with the client name, strain
name, genetic background, allelic status, cryopreservation date, embryo number and stage of development. This information is
also recorded in a database, with the number of straw, embryos per straw, storage location (container, canister, visotube)…
Efficiency of the technique: test thaw quality control to live pups
The ultimate goal is the revitalization of transgenic lines. But embryo viability depends not only on the cryopreservation
process but also to the genetic background and the presence of a transgene. So embryo survival is monitored for each line: i) in
vitro developmental rates are noted immediately after thawing and after one hour of culture, and ii) survival embryos are used
for in vivo control by performing embryo transfers. For this in vivo control, 15-25 two-cell-stage embryos are transferred to post
coïtum pseudopregnant fosther mother and the rate of live-born pups is observed. These tests are repeated twice.
An appropriate number of embryos are vitrified in order to obtain between 30 and 50 live-born pups. Optimally, 250
(homozygote strain) or 500 (heterozygous strain) embryos need to be cryopreserved. These effectives have been determined in
absence of embryo lethality or a reduced prolificacy related to the transgene. In absence of interference between the




P. Vanderzwalmen, D. Connan, L. Grobet, B. Wirtleitner, B. Remy, S. Vanderzwalmen, N. Zech,
and F. Ectors., 2013. Lower intracellular concentration of cryoprotectants after vitrification
than after slow freezing despite exposure to higher concentration of cryoprotectant solutions.
Accepted for publication in “Human Reproduction”.
COMMISSION DIRECTIVE 2006/17/EC of 8 February 2006. Implementing Directive 2004/23/EC of
the European Parliament and of the Council as regards certain technical requirements for the
donation, procurement and testing of human tissues and cells.
COMMISSION DIRECTIVE 2006/86/EC of 24 October 2006. Implementing Directive 2004/23/EC
of the European Parliament and of the Council as regards traceability requirements, notification
of serious adverse reactions and events and certain technical requirements for the coding,
processing, preservation, storage and distribution of human tissues and cells.
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